13.8
吸入麻酔薬は、吸入すると全身麻酔を誘発する薬剤です。GABA_A 受容体の感受性を高めるか、NMDA 受容体を阻害することで作用し、中枢神経系の活動を低下させます。吸入ガスの濃度を変えることで、麻酔の深さを素早く調整できます。吸入麻酔薬の一般的な例としては、イソフルラン、デスフルラン、セボフルランな…
吸入麻酔薬は、肺胞や組織全体に急速に拡散する吸入ガスや揮発性液体を通じて全身麻酔を誘発します。
これらの薬剤の麻酔効力は、最小肺胞濃度に依存します。これらの麻酔薬の分布には、肺胞の洗浄とそれに続く急速な組織の取り込みが含まれます。
それらは急な用量反応曲線と狭い治療指数を示し、既知の拮抗薬はありません。.
現代の薬剤には、イソフルラン、デスフルラン、セボフルランなどの揮発性液体、および亜酸化窒素などのガスが含まれます。それらは不燃性、非爆発性であり、廃棄物を最小限に抑えるために再循環システムを介して供給されます。
これらの薬剤は、NMDA受容体を阻害する亜酸化窒素を除き、GABAのGABA受容体に対するGABAの作用を増強することにより、脳血管抵抗と呼吸ドライブを減少させます。
これらの薬剤には、低血圧、呼吸器刺激、腎毒性などの潜在的な副作用があります。ハロゲン化炭化水素への曝露は、まれで生命を脅かす状態である悪性高体温症を引き起こす可能性があります。
特に、ほとんどの吸入麻酔薬は変化せずに大気中に放出されるため、環境に深刻な影響を与えます。
View the full transcript and gain access to JoVE Core videos
Q1: How do inhalational anesthetics induce general anesthesia?
Inhalational anesthetics induce general anesthesia through inhaled gases and volatile liquids that diffuse rapidly across pulmonary alveoli into tissues. Most agents enhance GABA's action on GABAA receptors, decreasing central nervous system activity. Nitrous oxide uniquely inhibits NMDA receptors instead. The depth of anesthesia can be rapidly adjusted by changing the inhaled gas concentration.
Q2: What is minimum alveolar concentration and why does it matter?
Minimum alveolar concentration (MAC) is the measure of anesthetic potency, determining how much inhaled anesthetic is needed for effect. It varies based on patient factors like age, temperature, and concurrent drug use. Agents with lower MAC values are more potent. This metric helps clinicians select appropriate anesthetics and dosing for individual patients.
Q3: What are the main types of modern inhalational anesthetics?
Modern inhalational anesthetics include volatile liquids such as isoflurane, desflurane, and sevoflurane, plus gases like nitrous oxide. Isoflurane causes dose-dependent hypotension with a pungent odor. Desflurane offers rapid onset and recovery due to low blood solubility. Sevoflurane has low pungency and is preferred for pediatric inhalation induction.
Q4: What adverse effects are associated with inhalational anesthetics?
Inhalational anesthetics can cause hypotension, respiratory irritation, and organ toxicity including nephrotoxicity. Exposure to halogenated hydrocarbons may trigger malignant hyperthermia, a rare but life-threatening condition. Metabolism can generate toxic metabolites, prompting replacement with less toxic alternatives. These risks require careful patient selection and monitoring during anesthesia.
Q5: Why are inhalational anesthetics a concern for the environment?
Most inhalational anesthetics are released unchanged into the atmosphere as greenhouse gases, contributing to global warming and climate change. Their environmental persistence and potency as climate agents have prompted efforts to minimize their use and atmospheric release. This environmental impact influences anesthetic selection in clinical practice.
Q6: How are inhalational anesthetics distributed and delivered in the body?
Inhalational anesthetics distribute through alveolar wash-in followed by rapid tissue uptake. They exhibit steep dose-response curves and narrow therapeutic indices ranging from 2 to 4, with no known antagonists. Modern agents are delivered via recirculation systems to minimize waste. This distribution pattern allows rapid onset and offset of anesthetic effects.
Q7: What factors influence the selection of a specific inhalational anesthetic?
Selection involves balancing the patient's pathophysiology against the drug's side-effect profile. Clinicians consider factors like age, temperature, concurrent medications, and the procedure duration. Sevoflurane is preferred for pediatric patients due to low pungency, while desflurane suits short procedures. The goal is maintaining optimal brain partial pressure while minimizing adverse effects.